Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for ...

The move is part of the company’s plan to renegotiate drug prices across other developed nations ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...